Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to $48.3 million.

  • Day One Biopharmaceuticals' Share-based Compensation fell 17.25% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $48.3 million for FY2024, which is 22.68% up from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Share-based Compensation is $48.3 million, which was up 22.68% from $39.3 million recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Share-based Compensation high stood at $48.3 million for FY2024, and its period low was $526,000 during FY2020.
  • In the last 3 years, Day One Biopharmaceuticals' Share-based Compensation had a median value of $39.3 million in 2023 and averaged $38.3 million.
  • Data for Day One Biopharmaceuticals' Share-based Compensation shows a peak YoY spiked of 2,432.51% (in 2021) over the last 5 years.
  • Day One Biopharmaceuticals' Share-based Compensation (Yearly) stood at $526,000 in 2020, then surged by 2,432.51% to $13.3 million in 2021, then spiked by 104.50% to $27.2 million in 2022, then spiked by 44.41% to $39.3 million in 2023, then increased by 22.68% to $48.3 million in 2024.